GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Name: GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Published: 2021
License: Public Domain

GI Innovation, Inc. · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

cervical-cancer immunotherapy pembrolizumab

advanced solid tumor, metastatic solid tumor, cervical cancer, urothelial carcinoma, clear cell renal cell cancer (ccrcc), squamous cell non small cell lung cancer, gi-101/gi-101a, cd80-igg4 fc-il2 variant, immunotherapy, il-2, interleukin-2, pembrolizumab

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 905121
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.